JP2008535835A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535835A5
JP2008535835A5 JP2008505262A JP2008505262A JP2008535835A5 JP 2008535835 A5 JP2008535835 A5 JP 2008535835A5 JP 2008505262 A JP2008505262 A JP 2008505262A JP 2008505262 A JP2008505262 A JP 2008505262A JP 2008535835 A5 JP2008535835 A5 JP 2008535835A5
Authority
JP
Japan
Prior art keywords
amino
formula
compound
thiazolo
thio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008505262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535835A (ja
JP5165553B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2006/000399 external-priority patent/WO2006107258A1/en
Publication of JP2008535835A publication Critical patent/JP2008535835A/ja
Publication of JP2008535835A5 publication Critical patent/JP2008535835A5/ja
Application granted granted Critical
Publication of JP5165553B2 publication Critical patent/JP5165553B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2008505262A 2005-04-06 2006-04-03 新規な5−置換された7−アミノ[1,3]チアゾロ[4,5−d]ピリミジン誘導体 Expired - Lifetime JP5165553B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0500767 2005-04-06
SE0500767-9 2005-04-06
PCT/SE2006/000399 WO2006107258A1 (en) 2005-04-06 2006-04-03 Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Publications (3)

Publication Number Publication Date
JP2008535835A JP2008535835A (ja) 2008-09-04
JP2008535835A5 true JP2008535835A5 (https=) 2009-06-04
JP5165553B2 JP5165553B2 (ja) 2013-03-21

Family

ID=37073739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008505262A Expired - Lifetime JP5165553B2 (ja) 2005-04-06 2006-04-03 新規な5−置換された7−アミノ[1,3]チアゾロ[4,5−d]ピリミジン誘導体

Country Status (30)

Country Link
US (2) US7947693B2 (https=)
EP (1) EP1869056B1 (https=)
JP (1) JP5165553B2 (https=)
KR (1) KR101335055B1 (https=)
CN (1) CN101193897B (https=)
AR (1) AR055890A1 (https=)
AT (1) ATE487727T1 (https=)
AU (1) AU2006231836B2 (https=)
BR (1) BRPI0609738A2 (https=)
CA (1) CA2604017C (https=)
CY (1) CY1111316T1 (https=)
DE (1) DE602006018124D1 (https=)
DK (1) DK1869056T3 (https=)
ES (1) ES2354450T3 (https=)
HR (1) HRP20110047T1 (https=)
IL (1) IL185912A0 (https=)
MX (1) MX2007012060A (https=)
NO (1) NO20075603L (https=)
NZ (1) NZ561460A (https=)
PL (1) PL1869056T3 (https=)
PT (1) PT1869056E (https=)
RS (1) RS51581B (https=)
RU (1) RU2419623C2 (https=)
SA (1) SA06270072B1 (https=)
SI (1) SI1869056T1 (https=)
TW (1) TW200714605A (https=)
UA (1) UA90707C2 (https=)
UY (1) UY29454A1 (https=)
WO (1) WO2006107258A1 (https=)
ZA (1) ZA200708187B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
RU2437889C2 (ru) * 2006-09-29 2011-12-27 Астразенека Аб НОВЫЕ 5,7-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2-(3Н)-АМИНА И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
AU2009221063B2 (en) 2008-03-07 2013-03-21 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, and CX3CR1
JP5509100B2 (ja) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な1−ベンジル−3−ヒドロキシメチルインダゾール誘導体及びそのMCP−1,CX3CR1及びp40の発現に基づく疾病の治療への使用
EA019711B1 (ru) 2008-03-07 2014-05-30 Ацьенде Кимике Рьюните Анджелини Франческо A.K.P.A.Ф. С.П.А. ПРОИЗВОДНЫЕ 1-БЕНЗИЛ-3-ГИДРОКСИМЕТИЛИНДАЗОЛА, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, ОБУСЛОВЛЕННЫХ ЭКСПРЕССИЕЙ МСР-1, СХ3CR1 ИЛИ р40
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
JP6076913B2 (ja) 2010-12-07 2017-02-08 ドレクセル ユニバーシティ 癌からの転移を阻害する方法
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
TWI543975B (zh) 2011-09-13 2016-08-01 Eisai R&D Man Co Ltd Pyrrolidin-3-yl acetic acid derivatives
ES2642805T3 (es) 2013-03-12 2017-11-20 Eisai R&D Management Co., Ltd. Sal de un derivado del ácido pirrolidín-3-ilacético y cristales de esta
BR112016006319A2 (pt) 2013-09-27 2017-08-01 Nimbus Iris Inc inibidores de irak e usos dos mesmos
WO2016200939A1 (en) * 2015-06-08 2016-12-15 The Johns Hopkins University Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1)
US11267817B2 (en) 2017-05-02 2022-03-08 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
GB201807898D0 (en) 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
GB201811169D0 (en) * 2018-07-06 2018-08-29 Kancera Ab New compounds
GB202006849D0 (en) 2020-05-08 2020-06-24 Kancera Ab New use
PE20251587A1 (es) 2022-10-19 2025-06-16 Astrazeneca Ab 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1
WO2025219939A1 (en) 2024-04-17 2025-10-23 Astrazeneca Ab Salts and polymorphs of cx3cr1 modulators
WO2025219950A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Small molecule cx3cr1 modulators
WO2025219947A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Thio-substituted 1,3,5-triazine cx3cr1 modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE543978A (https=) 1955-01-03
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4639433A (en) 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
CA2031803C (en) 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
EP0891978B1 (en) * 1997-07-18 2002-03-20 F. Hoffmann-La Roche Ag 5H-Thiazolo (3,2-a) pyrimidine derivatives
WO1999051608A1 (en) 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
WO1999056760A1 (en) 1998-05-01 1999-11-11 Eli Lilly And Company N1-modified glycopeptides
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
DE60101372T2 (de) * 2000-02-11 2004-10-14 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
SE0004110L (sv) 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US8110209B2 (en) * 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
CA2541533A1 (en) * 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
US20090239882A1 (en) * 2004-12-17 2009-09-24 Astrazeneca Ab Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos

Similar Documents

Publication Publication Date Title
JP2008535835A5 (https=)
CA2604017A1 (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
JP2008535834A5 (https=)
US9133128B2 (en) Pyrazole derivatives as cannabinoid receptor 1 antagonists
TWI404721B (zh) 胺基-雜環化合物
CN1832948B (zh) 1-烷基-1-氮*双环[2.2.2]辛烷氨基甲酸酯衍生物及其用作蕈毒碱受体拮抗剂的用途
JP2017518981A5 (https=)
JP2004528312A5 (https=)
CN102387704A (zh) S1p5受体的激动剂和拮抗剂,和其用法
RU2007140552A (ru) НОВЫЕ ПРОИЗВОДНЫЕ 5, 7-ДИЗАМЕЩЕННОГО [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2(3H)-ОНА
JP2005516067A5 (https=)
JP2014528433A5 (https=)
KR20160038008A (ko) 브로모도메인 억제제로서 신규 퀴나졸리논
JP2005525323A5 (https=)
JP2005536475A5 (https=)
EA010596B1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
JP2006522747A5 (https=)
JP2006522749A5 (https=)
JP2006523216A5 (https=)
IL273169B1 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
JP2010504344A5 (https=)
JP2011500621A5 (https=)
JP2005525322A5 (https=)
CA2660529A1 (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
JP2008539268A5 (https=)